Erratum to Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis [Inflammation, DOI 10.1007/s10753-015-0132-2];Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis

Inflammation

Volumn 38, Issue 4, 2015, Pages 1573-1579

  Peled, Michael ^a   Strazza, Marianne ^a   Azoulay Alfaguter, Inbar ^a   Mor, Adam ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

PD 1; psoriatic arthritis; signaling

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; RAP1 PROTEIN; PDCD1 PROTEIN, HUMAN;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DAS28; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; JOINT SWELLING; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; AGED; ARTHRITIS, PSORIATIC; BIOSYNTHESIS; CASE CONTROL STUDY; CELL CULTURE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ARTHRITIS, PSORIATIC; BIOMARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; YOUNG ADULT;

EID: 84937252297     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0165-6     Document Type: Erratum

References (25)

1. Liu, J.T., H.M. Yeh, S.Y. Liu, and K.T. Chen. 2014. Psoriatic arthritis: epidemiology, diagnosis, and treatment. World Journal of Orthopedics 5: 537–43.
2. Mease, P., M.C. Genovese, G. Gladstein, et al. 2011. Abatacept in the treatment of patients with psoriatic arthritis. Arthritis and Rheumatism 63: 939–48.
3. Kim, I.H., C.E. West, S.G. Kwatra, et al. 2012. Comparative efficacy of biologics in psoriasis. American Journal of Clinical Dermatology 13: 365–74.
4. Diani M, Altomare G, Reali E. 2014; Nov 28. T cell responses in psoriasis and psoriatic arthritis. Autoimmunity Reviews [Epub ahead of print].
5. Lee, M.L., S.T. To, A. Cooper, et al. 1993. Augmented lymphocyte binding to cultured endothelium in psoriasis. Clinical and Experimental Immunology 91: 346–50.
6. Iannone, F., and G. Lapadula. 2012. The inhibitor of costimulation of T cells: abatacept. The Journal of Rheumatology 39: 100–2.
7. Papoutsaki, M., and A. Costanzo. 2013. Treatment of psoriasis and psoriatic arthritis. BioDrugs 27: 3–12.
8. Mor, A., M.L. Dustin, and M.R. Philips. 2007. Small GTPases and LFA-1 reciprocally modulate adhesion and signaling. Immunological Reviews 218: 114–25.
9. Corse, E., and J.P. Allison. 2012. Cutting edge: CTLA-4 in effector T cells inhibits in trans. Journal of Immunology 189: 000–000.
10. Teft, W.A., M.G. Kirchof, and J. Madrenas. 2006. A molecular perspective of CTLA-4 function. Annual Review of Immunology 24: 65–97.
11. Parry, R.V., J.M. Chemnitz, K.A. Frauwirth, et al. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology 25: 9543–53.
12. Sharpe, A.H. 2009. Mechanism of costimulation. Immunological Reviews 229: 5–11.
13. Azoulay-Alfaguter, I., M. Strazza, A. Pedoeem, and A. Mor. 2014. The coreceptor programmed death-1 inhibits T-cell adhesion by regulating Rap1. The Journal of Allergy and Clinical Immunology 6749: 110–9.
14. Pedoeem, A., I. Azoulay-Alfaguter, M. Strazza, G.J. Silverman, and A. Mor. 2014. Programmed death-1 pathway in cancer and autoimmunity. Clinical Immunology 153: 145–52.
15. Mor, A., J.P. Wynne, I.M. Ahearn, et al. 2009. Phospholipase D1 regulates lymphocyte adhesion via upregulation of Rap1 at the plasma membrane. Molecular and Cellular Biology 29: 3297–306.
16. Taylor, W.J., and P.C. Robinson. 2013. Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis. Current Rheumatology Reports 15: 317.
17. Choy, E. 2007. T cells in psoriatic arthritis. Current Rheumatology Reports 9: 437–41.
18. van Riel, P.L. 2014. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clinical and Experimental Rheumatology 32: 65–74.
19. Riley, J.L. 2009. PD-1 signaling in primary T cells. Immunological Reviews 229: 114–25.
20. Chen, C.H., D.T. Yu, and C.T. Chou. 2009. Biomarkers in spondyloarthropathies. Advances in Experimental Medicine and Biology 649: 122–32.
21. Agrawal, A., H. Cha-Molstad, D. Samols, and I. Kushner. 2001. Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein beta (C/EBP beta) and Rel p50. Journal of Immunology 166: 2378–84.
22. Yang M, Zou Y, Bai Y, Li M. 2014; Oct 1. The programmed cell death 1 gene polymorphisms (PD 1.3 G/A, PD 1.5 C/T and PD 1.9 C/T) and susceptibility to ankylosing spondylitis: a meta-analysis. Journal of Orthopaedic Science [Epub ahead of print].
23. Kristjansdottir, H., K. Steinsson, I. Gunnarsson, G. Gröndal, K. Erlendsson, and M.E. Alarcón-Riquelme. 2010. Lower expression levels of the programmed death 1 receptor on CD4 + CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis and Rheumatism 62: 1702–11.
24. Chen Y, Li S, Su L, Sheng J, Lv W, Chen G, Xu Z. 2015; Jan 13. Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. Journal of Neurology [Epub ahead of print].
25. Bertsias, G.K., M. Nakou, C. Choulaki, A. Raptopoulou, E. Papadimitraki, G. Goulielmos, H. Kritikos, P. Sidiropoulos, M. Tzardi, D. Kardassis, C. Mamalaki, and D.T. Boumpas. 2009. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis and Rheumatism 60: 207–18.